Melbourne biopharmaceutical company Opthea has completed the patient recruitment phase for the latest trial of its novel therapy for diabetic macular edema (DME). Read more
Major Melbourne study a world-first for AMD
An Australian-led study has received $5 million to undertake the world’s most intensive investigation into why a particular group of age-related macular degeneration (AMD) patients are at greater risk of vision loss. Read more
Novartis targets Europe for next-generation AMD treatment
Novartis’ new therapy for neovascular age-related macular degeneration (nAMD) has advanced part-way through the European regulatory process after winning the approval of independent advisors. Read more
Warmth may improve effectiveness of anti-VEGF injections
Inconsistent or ineffective age-related macular degeneration (AMD) treatments might be solved by an easy solution, according to new research from the California Institute of Technology. Read more
Australian biotech raises an additional $50 million for AMD drug
Melbourne-based biotech company Opthea has announced it has secured commitments from both Australian and international investors for an additional $50 million to put towards the development of its treatment for neovascular age-related macular degeneration (AMD). Read more
Biogen unveils plan to commercialise Eylea and Lucentis generics
Multinational biotech company Biogen has proposed a deal worth up to US$310 million (AU$453 m) to supply biosimilar treatments of Lucentis and Eylea to major global markets, including Australia. Read more
Traces of anti-VEGF drugs found in breast milk
Anti-vascular endothelial growth factor (anti-VEGF) drugs have been identified in breast milk, prompting warnings from the researchers that the use of these medications during breastfeeding could affect developing infants. Read more
Eye injections top of agenda for ‘scope of practice’ advisory group
Optometrists performing intravitreal injections is one of several key issues to be addressed by a newly formed Optometry Australia (OA) advisory committee established to identify future opportunities for the profession. Read more
Melbourne study to put new AMD tools under microscope
The University of Melbourne is recruiting optometrists to test new clinical tools, as well as an auditing system, it has developed for management of patients with age-related macular degeneration (AMD). Read more
FDA clears Novartis’ new treatment for nAMD
Novartis has secured US regulatory approval for Beovu, the company’s latest therapy for neovascular age-related macular degeneration (nAMD), following the drug’s comparable results in head-to-head trials with Eylea. Read more